Phase I Study of Telatinib (BAY 57-9352): Analysis of Safety, Pharmacokinetics, Tumor Efficacy, and Biomarkers in Patients With Colorectal Cancer

Vascular Cell - United Kingdom
doi 10.1186/2045-824x-3-16

Related search